Ilduc

Quick links to important sections

Ilduc

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ilduc

Property Description
Active ingredient Amlodipine
Form Oral tablet
Pharmacological class Calcium channel blocker (Dihydropyridine)
General purpose Management of arterial blood pressure
Origin Synthetic compound
Prescription Status Prescription-only (Rx-only)

Defining Ilduc: Active Ingredient and Pharmacological Class

The medicine Ilduc is a prescription-only medicine classified as an antihypertensive agent used in cardiovascular management. It is a single entity drug containing Amlodipine (typically as the besilate salt) as its sole active ingredient. The compound is a synthetic compound that belongs to the major therapeutic group known as calcium channel blockers (CCBs), specifically recognized as a dihydropyridine derivative. This classification is significant as Amlodipine demonstrates high selectivity for vascular smooth muscle. This attribute highlights the drug's suitability for patients requiring primary vascular regulation.

Composition and General Therapeutic Purpose

Ilduc is formulated for oral administration and is supplied as an oral tablet preparation. As a core cardiovascular medication, the general therapeutic purpose of the drug is to achieve sustained reduction in elevated arterial pressure, helping manage the overall workload on the heart. Amlodipine is globally recognized, being included on the universal list of essential medicines. The compound's wide acceptance signifies it is regarded as a core medicine necessary for managing fundamental public health needs.

Mechanism Principle and Unique Action

The preparation's action is fundamentally based on the selective inhibition of calcium ion influx through specific channels in the blood vessel walls. This interference with muscle contraction leads directly to vasodilation, which is the relaxation and widening of the arteries. This unique mechanism of effect results in a gradual onset and long duration of action compared to many earlier CCBs. The reduction in peripheral vascular resistance is the key benefit, alleviating the mechanical burden on the heart and helping maintain long-term cardiovascular stability.

Regulatory References

  1. WHO Essential Medicines List for Amlodipine

What side effects are possible with Ilduc?

Possible Side Effects and Safety Information

The official safety profile for Ilduc (Amlodipine) is defined by government regulatory documents, classifying potential adverse reactions by frequency and physiological system affected. These classifications structure the understanding of the medicine's risk profile, ranging from common, generally minor effects to rare, serious adverse events.


Frequency and System-Organ Classes

The most frequently reported adverse reaction is peripheral edema (swelling of the ankles or feet), which is classified as Very Common (occurring in more than 1 in 10 patients). Effects categorized as Common include headache, dizziness, somnolence, fatigue, nausea, abdominal pain, palpitations, and flushing. These reactions primarily affect the Vascular, Nervous, and Gastrointestinal System-Organ Classes.

Uncommon effects (ge 1/1,000 to <1/100) include insomnia, mood alteration, and rash. Adverse reactions are explicitly noted to be dose-related, particularly headache and edema, and certain cardiovascular events may be more likely upon initiation or dose escalation.


Serious Adverse Reactions and Restrictions

Regulatory labeling documents rare but clinically significant adverse reactions, such as hepatitis, pancreatitis, arrhythmias, and severe skin reactions, including Stevens-Johnson syndrome and Angioedema. Furthermore, the label specifies absolute Contraindications, restricting use in patients with known hypersensitivity to the drug, cardiogenic shock, severe hypotension, and obstruction of the outflow tract of the left ventricle (e.g., severe aortic stenosis).

Safety statements also address specific populations. For older adults, reduced clearance necessitates the use of the lowest possible starting dose. Patients with hepatic impairment require careful dose titration due to reduced drug clearance and prolonged elimination half-life.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation for Ilduc (Amlodipine) overdose focuses on the consequences of exaggerated pharmacological effects, which primarily manifest as severe circulatory instability. The documented overdose presentations include marked and prolonged systemic hypotension (low blood pressure) and excessive peripheral vasodilatation.


Life-Threatening Outcomes and Required Action

Overdose can lead to life-threatening outcomes, as regulators document the potential progression to shock and, rarely, the delayed onset of non-cardiogenic pulmonary oedema. For suspected overdosage, government guidance mandates that users seek immediate medical attention.

Urgent help is required when symptoms escalate to collapse, seizure, trouble breathing, or if the individual cannot be awakened. Users are instructed to call the poison control helpline or emergency services (911) in such severe cases.

Management and Monitoring

The established management approach is strictly symptomatic and supportive, as no specific antidote is known for Amlodipine; furthermore, hemodialysis is not likely to be of benefit. Officially described supportive measures include initiating active cardiovascular support, active cardiac and respiratory monitoring, and measures to restore blood pressure, such as elevation of extremities and the use of vasopressors (e.g., phenylephrine) under clinical supervision.

Therapeutic Uses of Ilduc

Ilduc (Amlodipine) is a foundational cardiovascular medicine generally used to help with conditions characterized by periods of heightened symptoms related to systemic imbalance and physical discomfort. The medication's uses are established for these conditions and may be part of long-term symptomatic management.

The medication is commonly used across domains where additional symptomatic support is needed, addressing conditions like essential hypertension (chronic high blood pressure) and various forms of angina pectoris, including both chronic stable and vasospastic angina. This supportive therapeutic action may help ease the impact of symptoms on daily comfort and contributes to easing the overall symptom load. This is relevant in clinical settings that involve chronic, long-term cardiovascular stress management in both adults and pediatric patients aged 6 to 17. The use of Ilduc may contribute to improved day-to-day comfort and assists with maintaining functional stability during symptomatic phases.


Quick Fact: Support for Vascular and Cardiac Strain Ilduc is used to address the two primary manifestations of cardiovascular strain: the systemic stress associated with chronic high pressure and the episodic pain of angina.

Regulatory References

  1. DailyMed full prescribing information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Ilduc — official regulatory information

The following criteria summarize the officially documented population eligibility and non-eligibility rules for Ilduc (Amlodipine) as stated in government regulatory documents.


Eligibility Classification Population Restriction or Rule
Contraindicated (Must not use) Patients with known hypersensitivity to amlodipine or other dihydropyridine derivatives [Source 1.4].
Patients experiencing severe hypotension, shock, or other acute circulatory instabilities [Source 2.3].
Patients with high-grade aortic stenosis or unstable heart failure after acute myocardial infarction [Source 2.3].
Lactation (Breast-feeding) is generally contraindicated [Source 1.5].
Conditional Use (Use with Caution) Patients with hepatic insufficiency (impaired liver function) require slow dosage titration, often starting at the lowest dose [Source 2.3].
Older adults (ge65 years) may require initiation at the low end of the dose range [Source 1.4].
Patients with heart failure or severe obstructive coronary artery disease require cautious use [Source 2.3].

Age-Related Eligibility

Ilduc is approved for use in adults for all labeled indications. For pediatric patients ages 6 to 17 years, use is established only for hypertension. Safety and efficacy have not been established in children younger than 6 years of age [Source 1.4].

Pregnancy Eligibility

The safety of Ilduc in human pregnancy has not been established. Use during pregnancy is only recommended when the potential benefit to the mother justifies the potential risk to the fetus, particularly when no safer alternative is available [Source 2.5].


Official regulatory documents define absolute contraindications based on drug sensitivity and acute hemodynamic instability. Eligibility is further structured by age and specific cautions for populations with organ impairment, ensuring descriptive clarity on who can and cannot use the medicine.

What should I know about interactions with other medicines?

Ilduc (ruxolitinib) can interact with many other medications, supplements, and certain foods, which may change how Ilduc or the other products work, potentially increasing side effects or reducing effectiveness. Always inform your healthcare provider about all prescription and nonprescription drugs, vitamins, supplements, and herbal products you are taking.

Medications That May Increase Ilduc Levels

Ilduc is primarily broken down in the liver by an enzyme system, cytochrome P450 3A4 (CYP3A4). Medicines that inhibit or slow down this enzyme system can lead to higher levels of Ilduc in the bloodstream, increasing the risk of side effects like low blood cell counts (myelosuppression). Dose adjustments for Ilduc may be necessary if taken with these strong CYP3A4 inhibitors. Examples include:

  • Certain Antifungals: Ketoconazole, fluconazole, itraconazole.
  • Certain Antibiotics: Clarithromycin, erythromycin.
  • Certain Calcium Channel Blockers: Diltiazem, verapamil.
  • Certain HIV/AIDS Medications

Medications That May Decrease Ilduc Levels

Medicines that induce or speed up the CYP3A4 enzyme system can lower the amount of Ilduc in the blood, potentially making it less effective. Examples include:

  • Certain Antibiotics: Rifampin.
  • Certain Anti-Seizure Medications: Phenytoin, carbamazepine, phenobarbital.
  • Corticosteroids: Dexamethasone.

Other Important Interactions

  • Live Vaccines: The use of live vaccines is generally not recommended during Ilduc treatment due to the immunosuppressive effects of the drug.
  • Grapefruit and Grapefruit Juice: Consumption of grapefruit or grapefruit juice should be avoided as it can increase Ilduc levels and the risk of adverse effects. St. John's wort, a herbal supplement, should also be avoided as it can decrease Ilduc levels.

Mechanism of Action

The mechanism of action for Ilduc is defined by its ability to engage and modulate specific inflammatory pathways, leading to a sustained modulation of the inflammatory cascade. The mechanism operates across three primary domains:

Targeted TNF-alpha Antagonism

Ilduc is a recombinant fusion protein that functions as a selective antagonist by binding to and neutralizing Tumor Necrosis Factor-alpha (TNF-alpha). By acting as a decoy receptor, Ilduc sequesters both soluble and membrane-bound TNF-alpha, preventing it from interacting with its native cellular receptors (TNFR1 and TNFR2) on key immune cells.

Inhibition of Downstream Inflammatory Cascades

The blockade of TNF-alpha signaling leads to the inhibition of core intracellular pathways, most notably the NF-kappaB cascade. This effect modulates systems where targeted pathway adjustment is required, suppressing the genetic instruction to produce an array of secondary inflammatory mediators and enzymes, thereby reducing the localized inflammatory stimulus.

Modulation of Destructive Physiological Effects

The resulting physiological effect includes the modulation of the tissue microenvironment via a reduction in cellular activity. The mechanism shifts cell phenotypes away from a high-activity pro-inflammatory state. This functional shift limits the downstream activity of matrix metalloproteinases (MMPs) and osteoclasts.

Dosage and Administration Information

The medicine Ilduc (Amlodipine) is approved for oral administration only, typically supplied as tablets in strengths of 2.5 mg, 5 mg, and 10 mg. The medication is designed for a once-daily schedule and must be taken at the same time every day to help maintain consistent blood levels.

Instruction Detail
Route of administration Oral (Tablet, solution, or suspension)
Dosing schedule Adult initial dose: 5 mg once daily. Maximum dose: 10 mg once daily.
Timing in relation to meals May be taken with or without food
Missed-dose rule Skip the forgotten dose and resume the next day at the usual time; do not take extra doses

The standard adult initial dose is 5 mg once daily, which can be increased to the maximum daily dose of 10 mg. Dosage adjustments, or titration steps, should generally be separated by a period of 7 to 14 days to allow for assessment of the patient's response.

For small, fragile, or older patients, and those with hepatic impairment, a lower starting dose of 2.5 mg once daily may be considered, and any dose increases should be approached with caution. For pediatric patients ages 6 to 17, the dose range is 2.5 mg to 5 mg once daily; doses exceeding 5 mg have not been formally studied in this group. Administration with grapefruit or grapefruit juice is generally not recommended due to the potential for increased bioavailability.

This administration protocol establishes a long-term, continuous oral regimen, defining the consistent daily schedule, precise dosage boundaries, and required time intervals for safe dose management.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ilduc

Evidence for Use in Essential Hypertension (Chronic High Blood Pressure)

The research base for Ilduc includes major, long-term Randomized Controlled Trials (RCTs), comparative studies, and large-scale observational cohorts. These studies were observed in large populations of adults and were designed to examine changes in systolic and diastolic blood pressure (BP). These comprehensive studies contribute to the broader evidence landscape by reporting patterns related to the measurement of blood pressure goals and monitored the rate of major cardiovascular events measured in those studies, such as stroke and myocardial infarction.

For children and adolescents aged 6 to 17 years, specific RCTs examined populations with hypertension. These trials primarily monitored specific BP measurements over short time intervals. While these trials provide context regarding short-term changes in this population, evidence for the very long-term effects on cardiovascular outcomes in children is still emerging.

Evidence for Use in Chronic Stable Angina

For individuals with chronic stable angina, research has focused on double-blind, placebo-controlled trials designed to specifically explore symptomatic changes in patients. These trials were studied in adults with confirmed stable angina. The primary outcomes studied included patient-reported outcomes describing perceived discomfort, such as the frequency of anginal episodes, and the total use of rescue medications.

Research Gaps and Areas of Uncertainty

While research is extensive, official sources acknowledge several areas where evidence is limited or certainty remains low. The results apply only to the populations studied, meaning findings do not guarantee similar outcomes for every individual. Follow-up durations were limited in some smaller trials, and the comparative evidence is lacking for certain new treatment pathways.

Specifically, the effect of Ilduc on long-term cardiovascular outcomes in children is still emerging. Furthermore, in the setting of coronary artery disease, the ability of the medicine to directly influence plaque progression (a surrogate outcome) was associated with mixed findings across different long-term trials.

Key Studies & References

  1. Highlights of Prescribing Information for Amlodipine (Norvasc) - U.S. Food and Drug Administration (FDA)

Frequently Asked Questions (FAQ)

Common questions about Ilduc (FAQ)

Q: How quickly does Ilduc usually start to show effects?

A: Ilduc begins working on the day it is first taken. Official pharmacological data indicates that the primary blood pressure-lowering effect becomes evident gradually, typically within 4 to 8 hours after taking a single dose. This is the initial onset, and the full benefit builds up over time.

Q: Are the side effects of Ilduc permanent?

A: Most common reported adverse effects of Ilduc are described in regulatory documents as reversible. Reactions such as peripheral edema (swelling), headache, and fatigue are often related to the dosage and typically resolve after the medication is discontinued.

Q: Do the side effects from Ilduc usually go away over time?

A: According to official patient information, some common effects, such as headache or flushing, may lessen or go away after the first few days or weeks of treatment. This adjustment period occurs as the body becomes accustomed to the medicine. Patients experiencing side effects that do not improve may consult a healthcare provider.

Q: What is the typical timeframe for seeing the full benefits of Ilduc?

A: The full therapeutic benefit of Ilduc is achieved gradually. Official prescribing information states that because the drug accumulates slowly, it typically takes 7 to 10 days of once-daily dosing to reach stable blood levels. This is why healthcare providers generally assess any dose changes over a period of 7 to 14 days.

Q: How long does Ilduc stay in your system after stopping?

A: Ilduc is known to have a long elimination half-life, meaning it is cleared from the body slowly. Pharmacokinetic studies show this half-life can range from 30 to 50 hours, resulting in the medicine remaining in the body for approximately 7 to 10 days after the final dose.

Q: Is Ilduc considered a strong medication?

A: Ilduc contains Amlodipine, which is recognized globally and included on the World Health Organization's List of Essential Medicines. This designation indicates it is regarded as a core medicine necessary for managing public health needs, and evidence from clinical studies supports its use.

Q: Is Ilduc the same as the over-the-counter medicine called Y?

A: Ilduc is classified by regulatory agencies as a prescription-only medicine (Rx-only). It is not available for purchase over the counter and requires a prescription from a licensed healthcare provider.

Q: Are there any long-term health concerns associated with Ilduc?

A: Ilduc is an established medication used for the chronic, long-term management of conditions like high blood pressure. Its safety profile is well-defined by regulatory documents, which monitor both common and rare adverse events over many years of use in clinical practice and studies.

Q: What are the most common reasons someone might be asked to stop taking Ilduc?

A: Since treatment with Ilduc is typically long-term, reasons for discontinuing the medicine are usually related to a lack of desired therapeutic response or the occurrence of side effects that are intolerable or severe. Changes to the medication regimen are managed under the supervision of a healthcare provider.

Q: Can Ilduc be taken with common vitamins or supplements?

A: Official information advises against combining Ilduc with the herbal supplement St. John's wort, as it can potentially affect the drug's levels. It is generally described in official guidance that patients should disclose all products to a healthcare provider to manage potential interactions.

Q: What are the main differences between Ilduc and an older class of drugs for the same condition?

A: Ilduc belongs to the dihydropyridine calcium channel blocker (CCB) class. This class works by selectively blocking calcium influx into blood vessels, which causes them to relax and widen. Regulatory-supported research notes that CCBs have a high selectivity for blood vessels, distinguishing them from other older classes of high blood pressure medicines.

Q: How is the effectiveness of Ilduc measured in research studies?

A: The primary way effectiveness is measured in research studies for hypertension is by tracking the change in both systolic and diastolic blood pressure measurements from baseline. For other conditions, such as angina, effectiveness is often measured by patient-reported outcomes, like the frequency of episodes and the use of rescue medications.

Q: Are there any specific lifestyle restrictions while using Ilduc?

A: Official documentation advises avoiding consumption of grapefruit or grapefruit juice due to the potential for drug interaction. Furthermore, treatment for high blood pressure is often managed in conjunction with lifestyle considerations, such as maintaining a healthy weight and diet.

Q: Does Ilduc affect blood pressure readings?

A: Ilduc is designed to lower elevated blood pressure, but it does not interfere with the actual process of blood pressure measurement itself. Studies show that its effect is sustained over the 24-hour dosing interval, helping to keep readings steady throughout the day.

Q: Is Ilduc a type of steroid?

A: No, Ilduc is classified as a Calcium Channel Blocker, which is an antihypertensive agent. Regulatory documents define it as a synthetic chemical compound, and it is not a steroid medicine.

Q: How is Ilduc different from a biologic medication?

A: Ilduc is defined by regulatory agencies as a synthetic chemical compound administered as an oral tablet. This differs from biologic medicines, which are complex drug products derived from living sources (like cells) and are typically given by injection or infusion.

Q: What is the average duration of treatment with Ilduc?

A: Ilduc is indicated for the treatment of chronic conditions like high blood pressure and chronic stable angina. Therefore, treatment is typically considered long-term or continuous to help maintain sustained control over the condition.

Q: Is it OK to travel across time zones while taking Ilduc?

A: Ilduc must be taken once daily at the same time every day to maintain consistent blood levels, according to official information. When traveling across significant time zones, maintaining this consistency may require adjustment, and planning is generally required to maintain a consistent schedule.

Q: Is Ilduc safe to take if I have diabetes?

A: Official prescribing information does not list diabetes as a contraindication. Furthermore, large-scale clinical studies have included the use of amlodipine-based regimens in patients with high blood pressure who also have diabetes for the purpose of maintaining blood pressure control.

Q: Can Ilduc be taken with cold and flu medicine?

A: Regulatory sources suggest careful use when combining Ilduc with any over-the-counter cold or flu medication. Some remedies contain ingredients known as sympathomimetics (like certain decongestants) which can potentially increase blood pressure, which would counteract the effects of Ilduc.

Q: Does Ilduc cause weight changes?

A: Weight changes (increase or decrease) are not listed among the most common adverse effects in official documents. However, the most frequently reported side effect is peripheral edema (swelling of the ankles or feet), which is fluid retention that can contribute to a measured weight increase.

Q: What are the conditions where Ilduc is specifically not recommended for use?

A: Regulatory documents list absolute Contraindications where the drug must not be used (e.g., cardiogenic shock, severe hypotension). Additionally, safety and efficacy have not been formally established in children younger than 6 years of age, meaning its use is not recommended for that specific population.

Q: Why does the prescribing information include warnings about rare side effects?

A: Official prescribing information is required to communicate the full safety profile of the medicine. Warnings about rare, serious adverse events are included to provide a complete and factual assessment of all potential risks identified through clinical studies and continuous post-market surveillance.

How should Ilduc be stored and disposed of?

How to Store and Dispose of Ilduc?

The storage and disposal of Ilduc (Amlodipine) tablets must strictly follow official regulatory instructions to maintain product stability and protect the environment.

Official Storage Requirements

Storage Condition Requirement
Temperature Range Controlled room temperature, between 15 C to 30 C (59 F to 86 F).
Protection Store away from excess heat and moisture. The product must be kept in a tightly closed, light-resistant container.
Safety Keep this medication out of the sight and reach of children and use only up to the stated expiry date.

Official Disposal Rules

Any unused or expired Ilduc must be disposed of in accordance with local pharmaceutical requirements and must not be flushed down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ilduc found in:

A-Z Index: